ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01FC01 | BioTech | Daratumumab - 400mg/20ml | 8899 | 167016/1 | DARZALEX | 400mg/20ml | 1 | Injectable concentrate for solution | Infusion | Mersaco | Cilag AG | Switzerland | 156,171,284 L.L | 2.44 | E2 | Janssen Cilag International NV | Belgium | 12/12/20 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01FC01 | BioTech | Daratumumab - 400mg/20ml | 8899/388 | 167016/1 | DARZALEX | 400mg/20ml | 1 | Injectable concentrate for solution | Infusion | Mersaco | Cilag AG | Switzerland | L.L | 2.44 | E2 | Janssen Cilag International NV | Belgium | 05/02/20 |